Global Oncology Biosimilars Market

Description

List of Tables

The global market for oncology biosimilars is estimated to grow from $9.6 billion in 2025 and projected to reach $17.5 billion by the end of 2030, at a compound annual growth rate (CAGR) of 12.6% from 2025 to 2030.

The North American market for oncology biosimilars is estimated to grow from $3.1 billion in 2025 and projected to reach $5.7 billion by the end of 2030, at a CAGR of 13.4% from 2025 to 2030.

The Asia-Pacific market for oncology biosimilars is estimated to grow from $2.5 billion in 2025 and projected to reach $4.8 billion by the end of 2030, at a CAGR of 14.1% from 2025 to 2030.

Report Scope

The report examines and segments the global oncology biosimilars market by indication, drug class, route of administration and distribution channel. It also provides insights into key emerging trends and potential growth drivers. The study focuses on indications such as breast, lung and blood cancers and others. By drug class, it focuses on granulocyte colony-stimulating factors, monoclonal antibodies, hematopoietic agents and others. By route of administration, the focus is on intravenous, subcutaneous and others. The report also examines hospital, retail and online pharmacies and others by distribution channel.

Included is a regional analysis of North America, Europe, Asia-Pacific, South America and the Middle East and Africa that evaluates the impact of AI adoption on the oncology biosimilars industry and market dynamics, including drivers, challenges and emerging trends, while highlighting product and performance enhancement innovations. The study concludes with an analysis of major companies in the market and their offerings.

It includes global revenue ($ million) for the base year 2024, estimated for 2025 and data for the forecast period 2026 through 2030.

Report Includes

140 data tables and 40 additional tables
In-depth analysis of the global market for oncology biosimilar drugs
Analyses of the global market trends, with historic revenue (sales figures) from 2022 to 2024, estimates for 2025 and projections of CAGRs through 2030
Estimates of the current market size and revenue prospects of the global market, along with a market share analysis by disease indication (cancer type), drug class, route of administration, distribution channel and region
Facts and figures about market dynamics, opportunities and deterrents, technological advances, regulations, innovations and standards and the impacts of macroeconomic variables
Impact analysis of the U.S. tariffs on the market for biologics used in cancer treatment and supportive care
Insights derived from Porter's Five Forces model, as well as global supply chain analyses
Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the ESG risk ratings and practices of leading companies
A relevant patent analysis, featuring key granted and published patents
Analysis of the industry structure, including companies' market shares and rankings, strategic initiatives, M&A activity and a venture funding outlook
Profiles of the leading companies, including Samsung Bioepis, Sandoz Group AG, Celltrion Inc., Amgen Inc., and Biocon Biologics Ltd.

Product Code: PHM286A

Chapter 1 Executive Summary

Market Outlook
Scope of Report
Market Summary
Market Dynamics and Growth Factors
Emerging Technologies
Segmental Analysis
Regional Analysis
Conclusion

Chapter 2 Market Overview

Current Market Overview
Future Outlook
Analysis of Macroeconomic Factors
Impact of U.S. Tariffs on the Market
Impact of the Ukraine-Russia War
Economic Growth and Development
Demographic Shifts
Healthcare Expenditure Trends
Inflation and Currency Fluctuations
Porter's Five Forces Analysis

Chapter 3 Market Dynamics

Overview
Market Drivers
Surge in Global Cancer Incidence
Expiration of Blockbuster Biologic Patents
Need for Cost-Effective Cancer Therapies
Demand for Targeted and Supportive Oncology Treatments
Market Restraints
Regulatory Complexity and Approval Hurdles
Patent Challenges and Legal Barriers
Pharmacy Benefit Manager Practices
Market Opportunities
Expansion into Emerging Markets
Development of Novel Biosimilar Combinations and Specialty Formulations

Chapter 4 Regulatory Landscape

Regulatory Framework
U.S.
Europe
India
Australia
Japan

Chapter 5 Emerging Technologies and New Developments

Overview
Emerging Technologies
Advanced Cell Line Engineering
Artificial Intelligence and Machine Learning in Biosimilar Development
Gene Editing and Synthetic Biology Approaches
Modular and Single-Use Bioreactors
Patent Analysis
Key Takeaways
Patents, by Year
Patents, by Leading Jurisdiction
Patents, by Leading Inventor

Chapter 6 Market Segmentation Analysis

Segmentation Breakdown
Global Oncology Biosimilars Market, by Indication
Key Takeaways
Breast Cancer
Lung Cancer
Blood Cancer
Others
Global Oncology Biosimilars Market, by Drug Class
Key Takeaways
Granulocyte Colony-Stimulating Factor
Monoclonal Antibodies
Hematopoietic Agents
Others
Global Oncology Biosimilars Market, by Route of Administration
Key Takeaways
Intravenous
Subcutaneous
Others RoA
Global Oncology Biosimilars Market, by Distribution Channel
Key Takeaways
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
Geographic Breakdown
Global Oncology Biosimilars Market, by Region
Key Takeaways
North America
Europe
Asia-Pacific
Middle East and Africa
South America

Chapter 7 Competitive Intelligence

Industry Structure
Company Share Analysis for Oncology Biosimilars Market
Strategic Analysis

Chapter 8 Sustainability in the Oncology Biosimilars Market: ESG Perspective

Introduction to ESG
Sustainability Trends and Initiatives of the Oncology Biosimilars Industry
Concluding Remarks

Chapter 9 Appendix

Methodology
Abbreviations
Company Profiles
ACCORD HEALTHCARE
ALVOTECH
AMGEN INC.
AMNEAL PHARMACEUTICALS LLC.
APOTEX INC.
BIOCAD
BIOCON BIOLOGICS LTD.
CELLTRION INC.
FRESENIUS KABI AG
PFIZER INC.
SAMSUNG BIOEPIS
SANDOZ GROUP AG
TEVA PHARMACEUTICAL INDUSTRIES LTD.
VIATRIS INC.
Emerging Start-ups/Market Disruptors

Product Code: PHM286A

List of Tables

Summary Table : Global Market for Oncology Biosimilars, by Region, Through 2030
Table 1 : Real GDP Growth, by Country, 2022-2025
Table 2 : Pricing Analysis for Oncology WAC and ASP, 2024
Table 3 : Patents Granted for Oncology Biosimilars, by Year, 2022-2025
Table 4 : Patents Granted for Oncology Biosimilars, by Top Jurisdiction, 2022-2025
Table 5 : Patents Granted for Oncology Biosimilars, by Top Inventor, 2022-2025
Table 6 : Global Market for Oncology Biosimilars, by Indication, Through 2030
Table 7 : Global Market for Breast Cancer, by Region, Through 2030
Table 8 : Global Market for Lung Cancer, by Region, Through 2030
Table 9 : Global Market for Blood Cancer, by Region, Through 2030
Table 10 : Global Market for Other Types of Cancer, by Region, Through 2030
Table 11 : Global Market for Oncology Biosimilars, by Drug Class, Through 2030
Table 12 : Global Market for Granulocyte Colony-Stimulating Factor, by Region, Through 2030
Table 13 : Global Market for Monoclonal Antibodies, by Region, Through 2030
Table 14 : Global Market for Hematopoietic Agents, by Region, Through 2030
Table 15 : Global Market for Other Drug Classes, by Region, Through 2030
Table 16 : Global Market for Oncology Biosimilars, by Route of Administration, Through 2030
Table 17 : Global Market for Intravenous Route of Administration, by Region, Through 2030
Table 18 : Global Market for Subcutaneous Route of Administration, by Region, Through 2030
Table 19 : Global Market for Other Routes of Administration, by Region, Through 2030
Table 20 : Global Market for Oncology Biosimilars, by Distribution Channel, Through 2030
Table 21 : Global Market for Hospital Pharmacies for Oncology Biosimilars, by Region, Through 2030
Table 22 : Global Market for Retail Pharmacies for Oncology Biosimilars, by Region, Through 2030
Table 23 : Global Market for Online Pharmacies for Oncology Biosimilars, by Region, Through 2030
Table 24 : Global Market for Other Distribution Channels for Oncology Biosimilars, by Region, Through 2030
Table 25 : Global Market for Oncology Biosimilars, by Region, Through 2030
Table 26 : North American Market for Oncology Biosimilars, by Indication, Through 2030
Table 27 : North American Market for Oncology Biosimilars, by Drug Class, Through 2030
Table 28 : North American Market for Oncology Biosimilars, by Route of Administration, Through 2030
Table 29 : North American Market for Oncology Biosimilars, by Distribution Channel, Through 2030
Table 30 : North American Market for Oncology Biosimilars, by Country, Through 2030
Table 31 : U.S. Market for Oncology Biosimilars, by Indication, Through 2030
Table 32 : U.S. Market for Oncology Biosimilars, by Drug Class, Through 2030
Table 33 : U.S. Market for Oncology Biosimilars, by Route of Administration, Through 2030
Table 34 : U.S. Market for Oncology Biosimilars, by Distribution Channel, Through 2030
Table 35 : Canadian Market for Oncology Biosimilars, by Indication, Through 2030
Table 36 : Canadian Market for Oncology Biosimilars, by Drug Class, Through 2030
Table 37 : Canadian Market for Oncology Biosimilars, by Route of Administration, Through 2030
Table 38 : Canadian Market for Oncology Biosimilars, by Distribution Channel, Through 2030
Table 39 : Mexican Market for Oncology Biosimilars, by Indication, Through 2030
Table 40 : Mexican Market for Oncology Biosimilars, by Drug Class, Through 2030
Table 41 : Mexican Market for Oncology Biosimilars, by Route of Administration, Through 2030
Table 42 : Mexican Market for Oncology Biosimilars, by Distribution Channel, Through 2030
Table 43 : European Market for Oncology Biosimilars, by Indication, Through 2030
Table 44 : European Market for Oncology Biosimilars, by Drug Class, Through 2030
Table 45 : European Market for Oncology Biosimilars, by Route of Administration, Through 2030
Table 46 : European Market for Oncology Biosimilars, by Distribution Channel, Through 2030
Table 47 : European Market for Oncology Biosimilars, by Country, Through 2030
Table 48 : German Market for Oncology Biosimilars, by Indication, Through 2030
Table 49 : German Market for Oncology Biosimilars, by Drug Class, Through 2030
Table 50 : German Market for Oncology Biosimilars, by Route of Administration, Through 2030
Table 51 : German Market for Oncology Biosimilars, by Distribution Channel, Through 2030
Table 52 : U.K. Market for Oncology Biosimilars, by Indication, Through 2030
Table 53 : U.K. Market for Oncology Biosimilars, by Drug Class, Through 2030
Table 54 : U.K. Market for Oncology Biosimilars, by Route of Administration, Through 2030
Table 55 : U.K. Market for Oncology Biosimilars, by Distribution Channel, Through 2030
Table 56 : French Market for Oncology Biosimilars, by Indication, Through 2030
Table 57 : French Market for Oncology Biosimilars, by Drug Class, Through 2030
Table 58 : French Market for Oncology Biosimilars, by Route of Administration, Through 2030
Table 59 : French Market for Oncology Biosimilars, by Distribution Channel, Through 2030
Table 60 : Italian Market for Oncology Biosimilars, by Indication, Through 2030
Table 61 : Italian Market for Oncology Biosimilars, by Drug Class, Through 2030
Table 62 : Italian Market for Oncology Biosimilars, by Route of Administration, Through 2030
Table 63 : Italian Market for Oncology Biosimilars, by Distribution Channel, Through 2030
Table 64 : Spanish Market for Oncology Biosimilars, by Indication, Through 2030
Table 65 : Spanish Market for Oncology Biosimilars, by Drug Class, Through 2030
Table 66 : Spanish Market for Oncology Biosimilars, by Route of Administration, Through 2030
Table 67 : Spanish Market for Oncology Biosimilars, by Distribution Channel, Through 2030
Table 68 : Rest of Europe Market for Oncology Biosimilars, by Indication, Through 2030
Table 69 : Rest of Europe Market for Oncology Biosimilars, by Drug Class, Through 2030
Table 70 : Rest of Europe Market for Oncology Biosimilars, by Route of Administration, Through 2030
Table 71 : Rest of Europe Market for Oncology Biosimilars, by Distribution Channel, Through 2030
Table 72 : Asia-Pacific Market for Oncology Biosimilars, by Indication, Through 2030
Table 73 : Asia-Pacific Market for Oncology Biosimilars, by Drug Class, Through 2030
Table 74 : Asia-Pacific Market for Oncology Biosimilars, by Route of Administration, Through 2030
Table 75 : Asia-Pacific Market for Oncology Biosimilars, by Distribution Channel, Through 2030
Table 76 : Asia-Pacific Market for Oncology Biosimilars, by Country, Through 2030
Table 77 : Chinese Market for Oncology Biosimilars, by Indication, Through 2030
Table 78 : Chinese Market for Oncology Biosimilars, by Drug Class, Through 2030
Table 79 : Chinese Market for Oncology Biosimilars, by Route of Administration, Through 2030
Table 80 : Chinese Market for Oncology Biosimilars, by Distribution Channel, Through 2030
Table 81 : Japanese Market for Oncology Biosimilars, by Indication, Through 2030
Table 82 : Japanese Market for Oncology Biosimilars, by Drug Class, Through 2030
Table 83 : Japanese Market for Oncology Biosimilars, by Route of Administration, Through 2030
Table 84 : Japanese Market for Oncology Biosimilars, by Distribution Channel, Through 2030
Table 85 : Indian Market for Oncology Biosimilars, by Indication, Through 2030
Table 86 : Indian Market for Oncology Biosimilars, by Drug Class, Through 2030
Table 87 : Indian Market for Oncology Biosimilars, by Route of Administration, Through 2030
Table 88 : Indian Market for Oncology Biosimilars, by Distribution Channel, Through 2030
Table 89 : South Korean Market for Oncology Biosimilars, by Indication, Through 2030
Table 90 : South Korean Market for Oncology Biosimilars, by Drug Class, Through 2030
Table 91 : South Korean Market for Oncology Biosimilars, by Route of Administration, Through 2030
Table 92 : South Korean Market for Oncology Biosimilars, by Distribution Channel, Through 2030
Table 93 : Australian Market for Oncology Biosimilars, by Indication, Through 2030
Table 94 : Australian Market for Oncology Biosimilars, by Drug Class, Through 2030
Table 95 : Australian Market for Oncology Biosimilars, by Route of Administration, Through 2030
Table 96 : Australian Market for Oncology Biosimilars, by Distribution Channel, Through 2030
Table 97 : Rest of Asia-Pacific Market for Oncology Biosimilars, by Indication, Through 2030
Table 98 : Rest of Asia-Pacific Market for Oncology Biosimilars, by Drug Class, Through 2030
Table 99 : Rest of Asia-Pacific Market for Oncology Biosimilars, by Route of Administration, Through 2030
Table 100 : Rest of Asia-Pacific Market for Oncology Biosimilars, by Distribution Channel, Through 2030
Table 101 : MEA Market for Oncology Biosimilars, by Indication, Through 2030
Table 102 : MEA Market for Oncology Biosimilars, by Drug Class, Through 2030
Table 103 : MEA Market for Oncology Biosimilars, by Route of Administration, Through 2030
Table 104 : MEA Market for Oncology Biosimilars, by Distribution Channel, Through 2030
Table 105 : MEA Market for Oncology Biosimilars, by Sub-region, Through 2030
Table 106 : Middle East Market for Oncology Biosimilars, by Indication, Through 2030
Table 107 : Middle East Market for Oncology Biosimilars, by Drug Class, Through 2030
Table 108 : Middle East Market for Oncology Biosimilars, by Route of Administration, Through 2030
Table 109 : Middle East Market for Oncology Biosimilars, by Distribution Channel, Through 2030
Table 110 : African Market for Oncology Biosimilars, by Indication, Through 2030
Table 111 : African Market for Oncology Biosimilars, by Drug Class, Through 2030
Table 112 : African Market for Oncology Biosimilars, by Route of Administration, Through 2030
Table 113 : African Market for Oncology Biosimilars, by Distribution Channel, Through 2030
Table 114 : South American Market for Oncology Biosimilars, by Indication, Through 2030
Table 115 : South American Market for Oncology Biosimilars, by Drug Class, Through 2030
Table 116 : South American Market for Oncology Biosimilars, by Route of Administration, Through 2030
Table 117 : South American Market for Oncology Biosimilars, by Distribution Channel, Through 2030
Table 118 : South American Market for Oncology Biosimilars, by Country, Through 2030
Table 119 : Brazilian Market for Oncology Biosimilars, by Indication, Through 2030
Table 120 : Brazilian Market for Oncology Biosimilars, by Drug Class, Through 2030
Table 121 : Brazilian Market for Oncology Biosimilars, by Route of Administration, Through 2030
Table 122 : Brazilian Market for Oncology Biosimilars, by Distribution Channel, Through 2030
Table 123 : Argentine Market for Oncology Biosimilars, by Indication, Through 2030
Table 124 : Argentine Market for Oncology Biosimilars, by Drug Class, Through 2030
Table 125 : Argentine Market for Oncology Biosimilars, by Route of Administration, Through 2030
Table 126 : Argentine Market for Oncology Biosimilars, by Distribution Channel, Through 2030
Table 127 : Rest of South America Market for Oncology Biosimilars, by Indication, Through 2030
Table 128 : Rest of South America Market for Oncology Biosimilars, by Drug Class, Through 2030
Table 129 : Rest of South America Market for Oncology Biosimilars, by Route of Administration, Through 2030
Table 130 : Rest of South America Market for Oncology Biosimilars, by Distribution Channel, Through 2030
Table 131 : Strategic Initiatives for Oncology Biosimilars Market, 2024-2025
Table 132 : Abbreviations Used in the Global Oncology Biosimilars Market
Table 133 : Accord Healthcare: Company Snapshot
Table 134 : Accord Healthcare: Product Portfolio
Table 135 : Alvotech: Company Snapshot
Table 136 : Alvotech: Financial Performance, FY 2023 and 2024
Table 137 : Alvotech: Product Portfolio
Table 138 : Alvotech: News/Key Developments, 2024-2025
Table 139 : Amgen Inc.: Company Snapshot
Table 140 : Amgen Inc.: Financial Performance, FY 2023 and 2024
Table 141 : Amgen Inc.: Product Portfolio
Table 142 : Amneal Pharmaceuticals LLC.: Company Snapshot
Table 143 : Amneal Pharmaceuticals LLC.: Financial Performance, FY 2023 and 2024
Table 144 : Amneal Pharmaceuticals LLC.: Product Portfolio
Table 145 : Amneal Pharmaceuticals LLC.: News/Key Developments, 2023-2025
Table 146 : Apotex Inc.: Company Snapshot
Table 147 : Apotex Inc.: Product Portfolio
Table 148 : Biocad: Company Snapshot
Table 149 : Biocad: Product Portfolio
Table 150 : Biocon Biologics Ltd.: Company Snapshot
Table 151 : Biocon Biologics Ltd.: Financial Performance, FY 2023 and 2024
Table 152 : Biocon Biologics Ltd.: Product Portfolio
Table 153 : Biocon Biologics Ltd.: News/Key Developments, 2023-2025
Table 154 : Celltrion Inc.: Company Snapshot
Table 155 : Celltrion Inc.: Financial Performance, FY 2023 and 2024
Table 156 : Celltrion Inc.: Product Portfolio
Table 157 : Celltrion Inc.: News/Key Developments, 2025
Table 158 : Fresenius Kabi AG: Company Snapshot
Table 159 : Fresenius Kabi AG: Product Portfolio
Table 160 : Fresenius Kabi AG: News/Key Developments, 2023-2025
Table 161 : Pfizer Inc.: Company Snapshot
Table 162 : Pfizer Inc.: Financial Performance, FY 2023 and 2024
Table 163 : Pfizer Inc.: Product Portfolio
Table 164 : Pfizer Inc.: News/Key Developments, 2023-2025
Table 165 : Samsung Bioepis: Company Snapshot
Table 166 : Samsung Bioepis: Product Portfolio
Table 167 : Samsung Bioepis: News/Key Developments, 2024
Table 168 : Sandoz Group AG: Company Snapshot
Table 169 : Sandoz Group AG: Financial Performance, FY 2023 and 2024
Table 170 : Sandoz Group AG: Product Portfolio
Table 171 : Sandoz Group AG: News/Key Developments, 2024-2025
Table 172 : Teva Pharmaceutical Industries Ltd.: Company Snapshot
Table 173 : Teva Pharmaceutical Industries Ltd.: Financial Performance, FY 2023 and 2024
Table 174 : Teva Pharmaceutical Industries Ltd.: Product Portfolio
Table 175 : Teva Pharmaceutical Industries Ltd.: News/Key Developments, 2023-2025
Table 176 : Viatris Inc.: Company Snapshot
Table 177 : Viatris Inc.: Financial Performance, FY 2023 and 2024
Table 178 : Viatris Inc.: Product Portfolio
Table 179 : List of a Few Emerging Startups

List of Figures

Summary Figure : Global Market Shares for Oncology Biosimilars, by Region, 2024
Figure 1 : Porter's Five Forces Analysis - Oncology Biosimilars Market
Figure 2 : Global Market Dynamics of Oncology Biosimilars
Figure 3 : Global Market Shares for Oncology Biosimilars, by Indication, 2024
Figure 4 : Global Market Shares for Breast Cancer, by Region, 2024
Figure 5 : Global Market Shares for Lung Cancer, by Region, 2024
Figure 6 : Global Market Shares for Blood Cancer, by Region, 2024
Figure 7 : Global Market Shares for Other Types of Cancer, by Region, 2024
Figure 8 : Global Market Shares for Oncology Biosimilars, by Drug Class, 2024
Figure 9 : Global Market Shares for Granulocyte Colony-Stimulating Factor, by Region, 2024
Figure 10 : Global Market Shares for Monoclonal Antibodies, by Region, 2024
Figure 11 : Global Market Shares for Hematopoietic Agents, by Region, 2024
Figure 12 : Global Market Shares for Other Drug Classes, by Region, 2024
Figure 13 : Global Market Shares for Oncology Biosimilars, by Route of Administration, 2024
Figure 14 : Global Market Shares for Intravenous Route of Administration, by Region, 2024
Figure 15 : Global Market Shares for Subcutaneous Route of Administration, by Region, 2024
Figure 16 : Global Market Shares for Other Routes of Administration, by Region, 2024
Figure 17 : Global Market Shares for Oncology Biosimilars, by Distribution Channel, 2024
Figure 18 : Global Market Shares for Hospital Pharmacies for Oncology Biosimilars, by Region, 2024
Figure 19 : Global Market Shares for Retail Pharmacies for Oncology Biosimilars, by Region, 2024
Figure 20 : Global Market Shares for Online Pharmacies for Oncology Biosimilars, by Region, 2024
Figure 21 : Global Market Shares for Other Distribution Channels for Oncology Biosimilars, by Region, 2024
Figure 22 : Global Market Shares for Oncology Biosimilars, by Region, 2024
Figure 23 : North American Market Shares for Oncology Biosimilars, by Country, 2024
Figure 24 : European Market Shares for Oncology Biosimilars, by Country, 2024
Figure 25 : Asia-Pacific Market Shares for Oncology Biosimilars, by Country, 2024
Figure 26 : MEA Market Shares for Oncology Biosimilars, by Sub-region, 2024
Figure 27 : South American Market Shares for Oncology Biosimilars, by Country, 2024
Figure 28 : Global Market Share Analysis for Oncology Biosimilars, by Major Companies, 2024
Figure 29 : Alvotech: Revenue Share, by Country/Region, FY 2024
Figure 30 : Amgen Inc.: Revenue Share, by Business Unit, FY 2024
Figure 31 : Amgen Inc.: Revenue Share, by Country/Region, FY 2024
Figure 32 : Amneal Pharmaceuticals LLC.: Revenue Share, by Business Unit, FY 2024
Figure 33 : Biocon Biologics Ltd.: Revenue Share, by Business Unit, FY 2024
Figure 34 : Biocon Biologics Ltd.: Revenue Share, by Country/Region, FY 2024
Figure 35 : Celltrion Inc.: Revenue Share, by Business Unit, FY 2024
Figure 36 : Celltrion Inc.: Revenue Share, by Country/Region, FY 2024
Figure 37 : Pfizer Inc.: Revenue Share, by Business Unit, FY 2024
Figure 38 : Pfizer Inc.: Revenue Share, by Country/Region, FY 2024
Figure 39 : Sandoz Group AG: Revenue Share, by Business Unit, FY 2024
Figure 40 : Sandoz Group AG: Revenue Share, by Country/Region, FY 2024
Figure 41 : Teva Pharmaceutical Industries Ltd.: Revenue Share, by Country/Region, FY 2024
Figure 42 : Viatris Inc.: Revenue Share, by Business Unit, FY 2024
Figure 43 : Viatris Inc.: Revenue Share, by Country/Region, FY 2024

Global Oncology Biosimilars Market

Description

Table of Contents

List of Tables

Report Scope

Report Includes

Table of Contents

Chapter 1 Executive Summary

Chapter 2 Market Overview

Chapter 3 Market Dynamics

Chapter 4 Regulatory Landscape

Chapter 5 Emerging Technologies and New Developments

Chapter 6 Market Segmentation Analysis

Chapter 7 Competitive Intelligence

Chapter 8 Sustainability in the Oncology Biosimilars Market: ESG Perspective

Chapter 9 Appendix

List of Tables

List of Figures